TC
KYNB

TFS Capital’s Kyntra Bio KYNB Stock Holding History

TFS Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,181
Closed -$954K – 121
2017
Q2 		$954K Sell
1,181
-607
-34% -$423K 0.37% 46
2017
Q1 		$1.1M Sell
1,788
-1,187
-40% -$723K 0.36% 75
2016
Q4 		$1.59M Sell
2,975
-607
-17% -$303K 0.43% 26
2016
Q3 		$1.85M Sell
3,582
-259
-7% -$122K 0.44% 21
2016
Q2 		$1.58M Buy
3,841
+3,446
+872% +$1.58M 0.29% 57
2016
Q1 		$210K Buy
+395
New +$197K 0.03% 749
2015
Q4 		– Sell
-3,666
Closed -$2.01M – 788
2015
Q3 		$2.01M Buy
3,666
+2,880
+366% +$1.74M 0.19% 158
2015
Q2 		$462K Buy
+786
New +$457K 0.05% 558

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TFS Capital's KYNB Position: Q3 2017 in Review

TFS Capital sold out of Kyntra Bio (KYNB) in Q3 2017, closing a stake of 1,181 shares — an estimated $954K sold.

TFS Capital first reported a position in KYNB in Q2 2015 and held it in 8 quarters. The position peaked at $2.01M in Q3 2015. 182 funds tracked by Wall St. Rank hold KYNB as of Q3 2017.

  • TFS Capital reported no remaining Kyntra Bio position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 1,181 Kyntra Bio shares in Q3 2017, an estimated $954K.
  • TFS Capital first reported a position in Kyntra Bio in Q2 2015 and held it in 8 quarters.
  • TFS Capital's Kyntra Bio position peaked at $2.01M in Q3 2015.
  • 182 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.